Working Parties
What is the EBMT?Related Meetings EBMT logo
MembershipRegistryWorking PartiesNurses GroupDirectoryTransplant GuidelinesCorporate Sponsorship
Chronic Leukaemia
Prospective Clinical Trials
Retrospective Studies
Members
Publications
Questionnaire
Study Administration
INTERGROUP CLL AUTOGRAFT TRIAL
MRC + SFGM + GCLLSG + EBMT

The value of autografting in younger patients with high risk CLL

This is a prospective randomised phase III trial designed to determine the outcome of autologous SCT compared to no further treatment at present in patients with high risk CLL who have reached a complete remission (CR), a very good partial remission (VGPR) or a nodular partial remission (NPR) (see appendix I for definitions) after first or second line therapy.


This trial is closed to inclusion.

Trial management center:

EBMT Clinical Trials Office Leiden (The Netherlands)
E-mail: ebmtcto@lumc.nl
Telnr: +31 71 526 9722
(German) Faxnumber: +49 180 500 290 623
(fax to E-mail system)

Study Co-ordinator: Michallet, M

Writing Committee: Dreger P (Kiel), Milligan DW (Birmingham), Kimby E (Huddinge), Meloni G (Rome), Michallet M (Lyon), Van't Veer Mars (Rotterdam), Montserrat E (Barcelona)

Statisticians: Brand R (Leiden), Richards S (Oxford)

Data Manager: Van Os M (Leiden)

Click on the links below to download relevant documents in format

 

 


What is the EBMT? | Related Meetings | Membership | Registry | Working Parties
Nurses Group | Directory | Transplant Guidelines | Corporate Sponsorship

HOME | SITE MAP | RELATED LINKS | CONTACT US